New drug S-740792 passes first safety check in healthy volunteers
NCT ID NCT06724978
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage study tested the safety and how the body handles a new drug called S-740792 in 99 healthy adults. Participants received single or multiple doses as a liquid or tablet, and some also took midazolam to check for drug interactions. The trial is complete and helps decide if further studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fortrea Clinical Research Unit, Inc.
Daytona Beach, Florida, 32117, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
S-740792
What this could lead to
If successful, this study could support further development of S-740792 for future diseases.
What could go wrong
This is an early phase 1 trial in healthy people, so it does not test effectiveness for any condition. The drug may still fail in later studies.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.